Loading
Cell biologist studying how the tumour's surroundings help cancer cells invade and resist drugs.
Erik Sahai is Principal Group Leader of the Tumour Cell Biology Laboratory at The Francis Crick Institute in London. His specialisms are the tumour microenvironment, cancer cell invasion, and drug resistance and plasticity, with an interest in the fibroblast marker FAP. He uses intravital imaging and computational models to study how fibroblasts interact with tumour cells, how cancer cells invade, and the non-genetic plasticity that lets them survive targeted therapy. His Nature Reviews Cancer paper set out a framework for understanding cancer-associated fibroblasts. His work explains how a tumour's surroundings help it spread and resist drugs. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| A framework for advancing our understanding of cancer-associated fibroblasts | Nature Reviews Cancer | 2020 |
Shares Break the neutrophil DNA nets that catch tumour cells after surgery, Soften the tissue that new metastases need in order to grow.
Shares Soften the tissue that new metastases need in order to grow, Match therapy to the type of scar-forming cell in the tumour, FAP.
Shares FAP, Epithelial-mesenchymal transition & drug efflux.
Shares FAP, Epithelial-mesenchymal transition & drug efflux.
Shares Match therapy to the type of scar-forming cell in the tumour, Epithelial-mesenchymal transition & drug efflux.
Shares The Francis Crick Institute, Epithelial-mesenchymal transition & drug efflux.
Shares FAP, Epithelial-mesenchymal transition & drug efflux.